Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00828204 (ClinicalTrials.gov)	January 2009	20/1/2009	Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects	An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects	Multiple Sclerosis	Device: single-use autoinjector with a prefilled liquid Avonex syringe;Device: Avonex prefilled syringe via manual IM injection;Drug: BG9418 (interferon beta-1a)	Biogen	NULL	Completed	18 Years	65 Years	All	95	Phase 3	United States
2	NCT00168714 (ClinicalTrials.gov)	February 2004	9/9/2005	Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)	Avonex Pregnancy Exposure Registry	Prenatal Exposure Delayed Effects;Multiple Sclerosis;Pregnancy	Drug: BG9418 (interferon beta-1a)	Biogen Idec	NULL	Completed	N/A	N/A	Female	329	N/A	United States